Maximizing management of patients with decompensated heart failure

Clinical Cardiology

Volumn 23, Issue 3 SUPPL., 2000, Pages

  Loh, E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Heart failure; Heart transplantation; Inotropic therapy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; HYDRALAZINE; INOTROPIC AGENT; ISOSORBIDE DINITRATE; MILRINONE;

ARTERY CATHETERIZATION; ARTICLE; CONGESTIVE HEART FAILURE; DIAGNOSTIC APPROACH ROUTE; DYSPNEA; HEALTH CARE COST; HEART INJURY; HEART OUTPUT; HEART PERFORMANCE; HEART TRANSPLANTATION; HEART VENTRICLE SEPTUM RUPTURE; LUNG EDEMA; MITRAL VALVE REGURGITATION; PRACTICE GUIDELINE; PULMONARY ARTERY; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033996288     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960231502     Document Type: Article

References (21)

1. American Heart Association: 1999 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 1998
2. Loh E: Treatment of Acute Pulmonary Edema. UpToDate 7.3. 1999. UpToDate, Inc.
3. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure): Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-2784
4. Smith RF, Johnson G, Ziesche S, Bhat G, Blankenship K, Cohn JN, for the V-HeFT VA Cooperative Studies Group: Functional capacity in heart failure. Comparison of methods for assessment and their relation to other indexes of heart failure. Circulation 1993;87(suppl VI):VI-88-VI-93
5. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83: 1A-38A
6. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327:669-677
7. Oates MB, Stanek EJ, DeNofrio D, Loh E, McGhan WF: Analysis of congestive heart failure patient preferences for treatment outcomes: Symptoms vs. survival (abstr 1081-13). J Am Coll Cardiol 1999;33(2 suppl A):181A-182A
8. Connors AFJ, Speroff T, Dawson NV, Thomas C, Harrell FEJ, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, Fulkerson WJJ, Vidaillet H, Broste S, Bellamy P, Lynn J, Knaus WA, for the SUPPORT Investigators: The effectiveness of right heart catheterization in the initial care of critically ill patients. J Am Med Assoc 1996;276:889-897
9. Dalen JE, Bone RC: Is it time to pull the pulmonary artery catheter? (Editorial). J Am Med Assoc 1996;276:916-918
10. Givertz MM, Hare JM, Loh E, Gauthier DF, Colucci WS: Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: A rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 1996;28:1775-1780
11. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR: Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998;31:1336-1340
12. Ewy GA: Inotropic infusions for chronic congestive heart failure. Medical miracles or misguided medicinals? J Am Coll Cardiol 1999;33:572-575
13. Marius-Nunez AL, Heaney L, Fernandez RN, Clark WA, Ranganini A, Silber E, Denes P: Intermittent inotropic therapy in an outpatient setting: A cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 1996;132:805-808
14. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, for the PROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325: 1468-1475
15. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew FI, DeMets DL, White BG, for the Vesnarinone Trial Investigators: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 1998;339:1810-1816
16. Stanek EJ, Kinky DE, Loh E, DeNofrio D, Gibson GA: Cost minimization analysis of milrinone vs. dobutamine treatment strategies as a bridge to heart transplant (abstr). J Card Fail 1999;5(suppl): 280A
17. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
18. CIBIS-II Investigators and Committees: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353:9-13
19. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353: 2001-2007
20. Goldstein DJ, Oz MC, Rose EA: Implantable left ventricular assist devices. N Engl J Med 1998;339:1522-1533
21. Lilleberg J, Sundberg S, Nieminen MS: Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1995;26(suppl 1):S63-S69